Dr. Mark Hyman on GLP‑1 drugs facing multiple lawsuits | CUOMO
Dr. Mark Hyman returned to NewsNation to discuss the surge of lawsuits and the future of GLP‑1 drugs. Ozempic, once hailed as a “miracle” weight‑loss medication, helped drive more than 31 million Americans to GLP‑1s despite early warnings he discussed on the show in 2023. Now, thousands of lawsuits allege the drugs caused serious health […]
Starting GLP-1s Leads to Healthier Choices at Grocery Store
The initiation of GLP-1 receptor agonists is associated with modest shifts away from ultraprocessed foods and toward items with fewer calories and smaller amounts of carbs, sugar, and saturated fat. Medscape Medical News
Cold weather, hot scams.
This week, hosts Dave Bittner, Joe Carrigan, and Maria Varmazis (also host of the T-Minus Space Daily show) are sharing the latest in social engineering scams, phishing schemes, and criminal exploits that are making headlines. Joe has two stories this week, starting with scammers cashing in on a Verizon outage by luring customers with fake […]
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong 2025 results with 7% sales growth
Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions. Sales in the fourth quarter increased by 8%, reflecting the positive momentum. Pharmaceuticals Division sales increased by 9% (3% in CHF), with Phesgo (breast cancer), Xolair (food allergies), Ocrevus (multiple sclerosis), Hemlibra (haemophilia […]
Serena Williams refuses to rule out tennis comeback in new interview
Serena Williams has refused to rule out a tennis comeback, just under two months after she definitively denied a return to the sport in which she won 23 Grand Slam singles titles. In December, the appearance of Williams’ name in the tennis anti-doping test pool, a prerequisite to returning to the sport, raised the possibility […]
Eli Lilly Gears Up for a Busy Year with a Diversified Pipeline
<div><p paraid=”1424849640″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{9}”><strong>By Irene Yeh </strong></p></div><div><p paraid=”326437554″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{15}”><strong>January 29, 2026</strong> | Earlier this month at the J.P. Morgan Healthcare Conference, Eli Lilly Chairman and CEO David Ricks spoke at a fireside chat and presented what the company has planned for 2026, which also marks its 150th anniversary. This year is expected to be a productive one in terms of clinical trial activity, wider availability of medicines, and expansion into new therapeutic areas. </p></div><div><p paraid=”1509187804″ paraeid=”{5577703c-f973-435e-a90c-8756a698f87f}{107}”><strong>Anti-Obesity Drugs </strong></p></div><div><p paraid=”1827316575″ […]
A small molecule PTER-selective inhibitor reduces food intake and body weight
PTER (phosphotriesterase-related) is an amidohydrolase that mediates catabolism of the anorexigenic taurine metabolite N-acetyltaurine. However, the structural basis of PTER ligand binding and catalysis remains unknown, limiting our ability to harness this pathway therapeutically. Here, we solve crystal structures of a eukaryotic PTER in apo and product-bound forms. These structures uncover an unexpected pocket homology […]
Navigating the complex relationship between statins, GLP-1, and glycemic control
A study linking statins, the microbiome, and blood sugar control doesn’t change clinical practice The post Navigating the complex relationship between statins, GLP-1, and glycemic control appeared first on Peter Attia.
Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic
Ozempic, Mounjaro, and Zepbound can drive impressive weight loss, but stopping them is often followed by rapid weight regain. Researchers found that people regain weight faster after quitting these drugs than after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone.
Incretin Based Therapy in Heart Failure with Preserved Ejection Fraction
Join the American Heart Association for an insightful session with Dr. Clyde Yancy and Dr. Dhruv Kazi. Recent clinical trials demonstrate the efficacy of incretin-based therapies (including GLP1-RA) in the care of HFpEF patients and their pivotal role in improving patient quality of life. Dr. Clyde Yancy discusses the latest evidence from these landmark trials […]